Key result
STAT3 inhibition abrogates cardiac fibrosis and dysfunction driven by βIV-spectrin loss and fibroblast activation.
Why the study?
The precise sequence of events underlying activation of cardiac fibroblasts in vivo and the role of the βIV-spectrin/STAT3 complex in maintaining fibroblast quiescence and regulating fibrosis remain unclear.
Does STAT3 inhibition reduce fibrosis and improve cardiac function in βIV-spectrin-deficient mouse models?
Does STAT3 inhibition reduce fibrosis and improve cardiac function in βIV-spectrin-deficient mouse models?
The βIV-spectrin/STAT3 complex is essential for maintaining a quiescent phenotype in cardiac fibroblasts, and its disruption promotes fibrosis and cardiac dysfunction that can be mitigated by STAT3 inhibition.
May inform STAT3-targeted antifibrotic approaches in cardiac disease; leaves open translation from mouse models to human therapies.
Increased fibrosis is a characteristic remodeling response to biomechanical and neurohumoral stress and a determinant of cardiac mechanical and electrical dysfunction in disease. Stress-induced activation of cardiac fibroblasts (CFs) is a critical step in the fibrotic response, although the precise sequence of events underlying activation of these critical cells in vivo remain unclear. Here, we tested the hypothesis that a βIV-spectrin/STAT3 complex is essential for maintenance of a quiescent phenotype (basal nonactivated state) in CFs. We reported increased fibrosis, decreased cardiac function, and electrical impulse conduction defects in genetic and acquired mouse models of βIV-spectrin deficiency. Loss of βIV-spectrin function promoted STAT3 nuclear accumulation and transcriptional activity, and it altered gene expression and CF activation. Furthermore, we demonstrate that a quiescent phenotype may be restored in βIV-spectrin-deficient fibroblasts by expressing a βIV-spectrin fragment including the STAT3-binding domain or through pharmacological STAT3 inhibition. We found that in vivo STAT3 inhibition abrogates fibrosis and cardiac dysfunction in the setting of global βIV-spectrin deficiency. Finally, we demonstrate that fibroblast-specific deletion of βIV-spectrin is sufficient to induce fibrosis and decreased cardiac function. We propose that the βIV-spectrin/STAT3 complex is a determinant of fibroblast phenotype and fibrosis, with implications for remodeling response in cardiovascular disease (CVD).
No takes yet. Share an insight, caveat, or question.
Patel et al. (2019) studied Cardiac fibrosis and dysfunction. βIV-spectrin deficiency and STAT3 inhibition vs. Wildtype / Vehicle was evaluated on Cardiac fibrosis and ejection fraction (p=<0.05). Loss of βIV-spectrin promotes STAT3 nuclear accumulation and cardiac fibroblast activation, leading to increased fibrosis and cardiac dysfunction that is abrogated by STAT3 inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: